Royalty Pharma officer proposes $239K share sale

The notice also lists four earlier common-stock sales by Marshall Urist between May 14 and July 1, 2026.

Rhea-AI Filing Summary

Royalty Pharma plc (RPRX) lists Officer Marshall Urist's proposed sale of 4,126 Class A ordinary shares, with an aggregate market value of $238,812.88 and Merrill Lynch named as broker. The shares are identified as an equity performance award granted by Royalty Pharma on August 5, 2026; the notice lists September 28, 2026, as the sale date. Shares outstanding were 445,277,344 as of September 28, 2026.

Key Figures

Proposed sale: 4,126 Class A ordinary shares Aggregate market value: $238,812.88 Shares outstanding: 445,277,344 shares +4 more

7 metrics

Proposed sale 4,126 Class A ordinary shares Sale date listed as September 28, 2026

Aggregate market value $238,812.88 For the proposed sale

Shares outstanding 445,277,344 shares As of September 28, 2026

Past common-stock sale 13,684 shares; $726,137.82 May 14, 2026

Past common-stock sale 13,684 shares; $721,837.21 May 20, 2026

Past common-stock sale 9,098 shares; $502,066.55 June 24, 2026

Past common-stock sale 9,099 shares; $508,453.82 July 1, 2026

Key Terms

Rule 144, Equity Performance Award, aggregate market value

3 terms

Rule 144 regulatory

"definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Equity Performance Award financial

"Class A Ordinary Shares; Equity Performance Award"

aggregate market value financial

"aggregate market value"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many RPRX shares did Marshall Urist propose to sell?

Marshall Urist's notice lists a proposed sale of 4,126 Class A ordinary shares, with an aggregate market value of $238,812.88. Merrill Lynch is named as broker, and September 28, 2026, is listed as the sale date.

What is the source of Marshall Urist's proposed RPRX sale shares?

The shares are identified as an equity performance award granted by Royalty Pharma on August 5, 2026, as part of the issuer's equity compensation program.

What RPRX common-stock sales did Marshall Urist report for the prior three months?

The listed sales were 13,684 shares on May 14, 2026, for $726,137.82; 13,684 shares on May 20 for $721,837.21; 9,098 shares on June 24 for $502,066.55; and 9,099 shares on July 1 for $508,453.82.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/28/2026 - 04:10 PM Accepted by SEC EDGAR 09/28/2026 - 04:09 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001838139
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Royalty Pharma plc
SEC File Number	001-39329
Address of Issuer	110 EAST 59TH STREET NEW YORK NEW YORK 10022
Phone	(212) 883-0200
Name of Person for Whose Account the Securities are To Be Sold	Urist Marshall
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty Street Floor 37 New York NY 10281	4126	238812.88	445277344	09/28/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Ordinary Shares	08/05/2026	Equity Performance Award	Royalty Pharma plc			4126	08/05/2026	Granted as part of issuer equity compensation program

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Marshall Urist 110 EAST 59TH STREET New York NY 10022	Common Stock	05/14/2026	13684	726137.82
Marshall Urist 110 EAST 59TH STREET New York NY 10022	Common Stock	05/20/2026	13684	721837.21
Marshall Urist 110 EAST 59TH STREET New York NY 10022	Common Stock	06/24/2026	9098	502066.55
Marshall Urist 110 EAST 59TH STREET New York NY 10022	Common Stock	07/01/2026	9099	508453.82

144: Remarks and Signature

Remarks
Date of Notice	09/28/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/26/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Marshall Urist
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)